Video - Results from #40

CRPC w/ Bone Metastases VL

Search

ERA 223: Presentation Summary from ESMO 2018 - Fred Saad Details (Length of Presentation: 8 min) Fred Saad presents: Abiraterone Acetate and Prednisone in Combination with Radium-223 or Placebo in Patients with Castration-Resistant Prostate Cancer in Bone Metastases: The Results of the Phase Three Trial. Biography: Fred Saad, MD FRCS, Full Professor and Chief of Urologic Oncology, Medical Director of Interdisciplinary Urologic Oncology Group, and Department of...
The Role of Bone Health Agents in Patients with Prostate Cancer - Tia Higano Details (Length of interview: 11 minutes) Tia Higano and Alicia Morgans share their perspective on the data analysis from the ERA-223 phase III study and highlight the value of incorporating bone health management, weight-bearing and resistance exercise when treating patients with prostate cancer. Biographies: Celestia (Tia) S. Higano, MD, Director, Prostate Cancer Clinical Research Group, Seattle Cancer...
A Renewed Analysis of ERA 223 - Fred Saad Details Charles Ryan and Fred Saad discuss the recent analysis of data points from ERA 223. (Length of Interview: 4 min) Biographies: Fred Saad, MD FRCS, Full Professor and Chief of Urologic Oncology, Medical Director of Interdisciplinary Urologic Oncology Group, Department of Surgery/Faculty of Medicine; Institut du cancer de Montréal/CRCHUM Charles J. Ryan, MD Referenced in this discussion: ERA 223 - A...
Prostate Cancer Osteomimicry in Circulating Tumor Cells in Men with Metastatic Castration Resistant Prostate Cancer (mCRPC) - Andrew Armstrong Details Andrew Armstrong and Alicia Morgans, discuss the PROPHECY trial, a prospective trial of circulating tumor cells, evaluating two current assays: the EPIC AR-V7 Nuclear Protein CTC and the Hopkins AR-V7 Adnatest. The conversation evolves to a discussion of the data from Armstrong's recent work shared at the 2018 ASCO GU meeting: measuring osteomimicry in three levels: RNA, DNA, and protein, potentia...
Updates on Health-Related Quality-of-Life (HRQoL) analyses in GU Oncology - Cora Sternberg Details Cora Sternberg highlights from a number of key treatments in GU Oncology in a discussion with Alicia Morgans. Results from the only Phase 3 health-related quality-of-life (HRQoL) analyses in urothelial carcinoma from the KEYNOTE-045 study delivers results for patients who received 2 nd line therapy. A relevant discussion follows on a Phase 2 trial investigating 3 different dosing regimens of radiu...
The State of Nuclear Medicine in the Treatment of Prostate Cancer - Interview with Oliver Sartor Details Charles Ryan, MD, and Oliver Sartor, MD discuss bone health in the treatment of prostate cancer and then transition to discuss the novel theranostic opportunities that are in development for the treatment of prostate cancer including Lutetium-177 PSMA and Actinium PSMA-225. Lastly, they have a concise conversation about DNA mutations in prostate cancer and the implications of germ-line and somatic...
Imaging Modality and Recommendations Included in RADAR 3: Interview with Phillip Koo Details (Length of Discussion: 13 min) Phillip Koo, MD, FACS joins Alicia Morgans, MD, MPH to discuss the RADAR 3 recommendations in regards to imaging and detecting metastatic disease in prostate cancer. Biographies: Phillip J. Koo, MD, FACS Alicia Morgans, MD, MPH Related Content: A Clinician’s Guide to Next Generation Imaging in Patients with Advanced Prostate Cancer (Prostate Cancer Radiographic Asses...